SSG
KYMR icon

Summit Securities Group’s Kymera Therapeutics KYMR Stock Holding History

Summit Securities Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-140
Closed -$3.83K – 1262
2025
Q1 		$3.83K Buy
+140
New +$5.1K ﹤0.01% 629

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Summit Securities Group's KYMR Position: Q2 2025 in Review

Summit Securities Group sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 140 shares — an estimated $3.83K sold.

Summit Securities Group first reported a position in KYMR in Q1 2025 and held it in 1 quarter. The position peaked at $3.83K in Q1 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Summit Securities Group reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 140 Kymera Therapeutics shares in Q2 2025, an estimated $3.83K.
  • Summit Securities Group first reported a position in Kymera Therapeutics in Q1 2025 and held it in 1 quarter.
  • Summit Securities Group's Kymera Therapeutics position peaked at $3.83K in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.